PATENT ENFORCEMENT: CELLTRUST V. IONLAKE – MYREPCHAT

 

UPDATE AUGUST 2024

In August 2024, CellTrust was victorious in the third-party challenge in front of the U.S. Patent and Trademark Office (“the USPTO”) for claims of U.S. Patent No.9,775,012 (“the ’012 Patent”) and claims of U.S. Patent No. 10,778,837 (“the ’837 Patent”) and received Ex Parte Reexamination Certificates from the USPTO.

The USPTO rejected the third-party’s challenge to the original patent claims, which remain the subject of other ongoing litigation. Even more, the USPTO confirmed the patentability of new patent claims that are not currently the subject matter of ongoing litigation.

 

MAY 2023

While the jury did not decide in CellTrust’s favor on eight of the 50 claims within the ‘012 and ‘837 patents, CellTrust believes that the results were contrary to and not supported by the evidence and intends to seek available post-verdict relief. CellTrust continues to believe in the strength of its patents and will vigorously enforce its intellectual property rights.

 

For patent licensing please contact: